European Medicines Agency 
Evaluation of Medicines for Human Use 
London, 22 October 2009 
Doc.Ref.EMEA/CHMP/681835/2009  
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE  
POST-AUTHORISATION SUMMARY OF POSITIVE OPINION* 
for  
KINZALMONO 
International Nonproprietary Name (INN):  telmisartan 
On  22  October  2009  the  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  adopted  a 
positive  opinion**  to  recommend  the  variation  to  the  terms  of  the  marketing  authorisation  for  the 
medicinal  product  Kinzalmono.  The  Marketing  Authorisation  Holder  for  this  medicinal  product  is 
Bayer Schering Pharma AG. 
The CHMP adopted a new indication as follows: 
“Cardiovascular prevention 
Reduction of cardiovascular morbidity in patients with:  
i) manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or 
peripheral arterial disease) or 
ii) type 2 diabetes mellitus with documented target organ damage”. 
Detailed conditions for the use of this product will be described in the updated Summary of Product 
Characteristics  (SPC)  which  will  be  published  in  the  revised  European  Public  Assessment  Report 
(EPAR)  and  will  be  available  in  all  official  European  Union  languages  after  the  variation  to  the 
marketing authorisation has been granted by the European Commission. 
* 
Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within  44 
days (Type II variations) and 67 days (Annex II applications) from adoption of the Opinion. 
**  Marketing Authorisation Holders may request a re-examination of any CHMP opinion, provided they notify the EMEA in writing of 
their intention to request a re-examination within 15 days of receipt of the opinion. 
7 Westferry Circus, Canary Wharf, London  E14 4HB, UK 
Tel. (44-20) 74 18 84 00  Fax (44-20) 74 18 86 68 
E-mail: mail@emea.europa.eu     http://www.emea.europa.eu 
© European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
                                                     
 
 
 
 
 
 
 
 
 
